NDMA & NDEA: What’s the Difference?

In July 2018, the FDA recalled certain batches of valsartan after investigators found N-Nitrosimethylamine (NDMA) had contaminated the drug. Since then, several batches of valsartan, irbesartan, and losartan have been recalled due to NDMA and N-Nitrosodiethylamine (NDEA) contamination. These nitrosamines are classified as probable human carcinogens.

How Are They Similar?

NDMA and NDEA are both classified by the Environmental Protection Agency as probable human carcinogens. Exposure to these carcinogens can cause tumors to develop in the respiratory tract. Specifically, an individual may develop liver, kidney, stomach, colorectal, and/or intestinal cancer.

What’s the Difference?

The main difference between NDMA and NDEA is toxicity. NDEA happens to be about three times more toxic than NDMA.

What Should I Do?

If you or a loved one took a recalled valsartan, irbesartan, or losartan and developed liver, kidney, stomach, colorectal, or intestinal cancer, please fill out the form below. We deliver the Gold standard advocacy you deserve.

Losartan Recalled Expanded: Ten Lots Recalled

On January 3, 2019, the FDA issued yet another recall of Losartan Potassium tablets. The first recall was issued November 9, 2018 and involved 2 lots. Now, Torrent Pharmaceuticals Limited is recalling a total of 10 lots due to the unexpected impurity N-nitrosodiethylamine (NDEA) found in the drug.

Losartan is a medication used to treat hypertension. It was recalled following the recall of similar drugs Valsartan and Irbesartan for containing NDEA and N-nitrosodimethylamine (NDMA). These substances are classified as probable human carcinogens by the Environmental Protection Agency. Exposure to NDEA can cause:

  • Liver cancer
  • Stomach cancer
  • Colon cancer
  • Kidney cancer
  • Intestinal Cancer

The products subject to recall can be found on the FDA’s website, which lists the product description, batch/lot number, and expiration date.

If you or a loved one was diagnosed with liver, kidney, stomach, colon, or intestinal cancer after taking Losartan, please contact us. We have over 30 years of experience handling dangerous drug cases. At GoldenbergLaw, we deliver the Gold standard advocacy you deserve.

Losartan Recalled: List of Recalled Sartan Drugs Continues to Grow

On November 9, 2018, the FDA issued a recall of Losartan due to carcinogen contamination concerns. Losartan is now the third “sartan” drug that has been recalled after the carcinogen N-Nitrosodiethylamine (NDEA) was detected in its active pharmaceutical ingredient.

The recalled lots of Losartan were manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd., the same company that manufactured the NDMA-contaminated Valsartan. Since then, the FDA has put Zhejiang Huahai Pharmaceutical on an import alert, meaning the FDA “has enough evidence to allow for Detention Without Physical Examination of products that appear to be in violation of FDA laws and regulations.”

NDEA is a probable human carcinogen and can cause:

  • Liver cancer
  • Kidney cancer
  • Stomach cancer
  • Colon/colorectal/intestinal cancer

If you or a loved one contracted liver, kidney, stomach, colorectal, or intestinal cancer after taking Losartan, contact GoldenbergLaw. Leave the sleepless nights to us.